pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

Experts say AI could outperform doctors on basic tasks by 2030

Aug 17, 2026·read at Endpoints ↗Neutral

Most clinical AI tools being built today are intended to work under a doctor's supervision.

Healthcare and venture-capital experts predict that by 2030 AI may independently perform better than physicians on certain basic medical tasks.

The outlook signals a potential shift toward more autonomous AI applications in patient care, according to the source.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “AI will be better than doctors at some medical tasks, healthcare and VC experts predict”

read at Endpoints ↗
88 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 5h agoDrugmakers voice support of US probe into Germany’s drug pricing plansEndpoints
  • 7h agoEyePoint’s bid to compete with Eylea falls flatEndpoints
  • 7h agoBiotech's reverse merger renaissance poised to continueEndpoints
  • 8h agoAstraZeneca touts separate late-stage lung cancer wins with Tagrisso, EnhertuEndpoints
  • 8h agoSummit, Akeso's ivonescimab shows smaller benefit with longer follow-up in ChinaEndpoints